Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Vuk Zdinjak

Khiron Reports Revenue Growth Of 59.6% In 2021, Gross Profit Improves 230% YoY

Khiron Life Sciences Corp. (OTCQX:KHRNF) (TSXV:KHRN) (Frankfurt:A2JMZC) released its financial results for the year ended and quarter ended December 31, 2021.

2021 Financial Highlights:

  • Net loss of CA$33.13 million ($25.67 million) compared to net loss of CA$24,04 million in 2020, an unfavorable increase of 37.81%.

  • Revenue of CA$12.8 million compared to CA$8.02 million in 2020

  • Adjusted EBITDA was a loss of CA$17.38 million compared to a loss of CA$18.76 million in 2020.

  • Gross profit before fair value adjustments was CA$4.91 million compared to CA$1.48 million in 2020, a favorable increase of 231.75%.

Q4 2021 Financial Highlights:

  • Net loss of CA$19.5 million compared to net loss of CA$2.37 million in Q4 2020, an unfavorable increase of 722.78%.

  • Revenue of CA$3.63 million compared to CA$2.52 million in Q4 2020

  • Adjusted EBITDA was a loss of CA$5.65 million compared to a loss of CA$4.34 million in Q4 2020.

  • Gross profit before fair value adjustments was CA$1.08 million compared to CA$402,000 in Q4 2020.

Related News

Cannabis Dispensary Roundup: Where To Buy Rec Marijuana In New Jersey, CBD Spas & More Store Openings

Khiron Opens New Zerenia Clinic And Medical Cannabis Pharmacy In Colombia

How Efficient Is Medicinal Cannabis As Treatment For Chronic Pain? Khiron's Clinical Study Reveals

Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.